Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Psoriasis (Auckland, N.Z.)|February 2, 2018
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic reviewGabrielle H Kingsley, David L ScottCurrent Opinion in Rheumatology|December 4, 2004
Use of imaging to assess patients with muscle diseaseDavid L Scott, Gabrielle H KingsleyThe Journal of Rheumatology|March 3, 2015
Calprotectin as a biomarker for rheumatoid arthritis: a systematic reviewMads Abildtrup, Gabrielle H Kingsley, David L ScottCurrent Opinion in Rheumatology|April 5, 2008
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritisPradip Nandi, Gabrielle H Kingsley, David L ScottClinical and Experimental Rheumatology|October 17, 2013
Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?Ian C Scott, Gabrielle H Kingsley, David L ScottEuropean Journal of Heart Failure|September 2, 2008
Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trialsPaul A Scott, Gabrielle H Kingsley, David L ScottRheumatology (Oxford, England)|November 18, 2009
A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritisMargaret H Y Ma, Gabrielle H Kingsley, David L ScottRheumatology (Oxford, England)|January 27, 2010
Fibromyalgic rheumatoid arthritis and disease assessmentLouise C Pollard, Gabrielle H Kingsley, Ernest H Choy, et al.The Journal of Rheumatology|June 3, 2010
Remission in early rheumatoid arthritisMargaret H Y Ma, Ian C Scott, Gabrielle H Kingsley, et al.Clinical and Experimental Rheumatology|February 14, 2012
Current limitations in the management of cardiovascular risk in rheumatoid arthritisIan C Scott, Fowzia Ibrahim, Deborah Johnson, et al.Pageof 2